Selank vs benzodiazepines — what the comparative anxiolytic trials show

Anxiolytic research has been dominated for sixty years by the GABA-A positive allosteric modulator class — benzodiazepines and their structural relatives. Any new anxiolytic candidate has to either match the benzodiazepine standard on anxiolytic potency or offer a meaningfully better side-effect profile to justify clinical development. Russian work on Selank explicitly framed the question this way, designing comparative trials against a benzodiazepine comparator rather than against placebo alone.

The comparator most commonly used in the Selank trial body is medazepam, an intermediate-potency benzodiazepine in routine clinical use for generalised anxiety in Russia at the time. Trials enrolled patients with generalised anxiety disorder or adjustment disorder with anxiety, randomised them to Selank or medazepam, and measured anxiolytic effect plus a battery of side-effect endpoints.

The primary endpoint across the trial body was anxiolytic effect, typically measured with the Hamilton Anxiety Rating Scale and the Spielberger State-Trait Anxiety Inventory. Secondary endpoints addressed the side-effect profile in detail: sedation (measured by daytime sleepiness scales), motor impairment (reaction-time and coordination tests), cognitive impairment (digit-symbol substitution and similar measures), and abuse liability (subjective drug-liking measures in some studies).

Trial durations were typically 10 to 14 days of treatment, with assessments at baseline, mid-treatment, and end of treatment. Follow-up windows varying from one to four weeks post-treatment looked for rebound anxiety on discontinuation.

The headline finding across the comparative trial body is that Selank produces anxiolytic effects comparable in magnitude to medazepam at the doses studied. Hamilton Anxiety Rating Scale reductions in the Selank arms matched or modestly exceeded the medazepam arms by end-of-treatment in the published studies, with statistical equivalence rather than superiority being the most defensible conclusion from the pooled data.

The time-course was different. Selank's anxiolytic effect develops gradually across the treatment course; medazepam produces a more rapid acute anxiolytic effect from the first dose. By the end of the two-week treatment window the magnitude was comparable; in the first few days, medazepam led on the anxiety measures. Research designs that prioritise acute anxiolysis would therefore still choose the benzodiazepine class; designs that can accept the slower onset can substitute Selank.

The substantive case for Selank rests on the side-effect comparisons rather than the anxiolytic-effect comparison. The published trials report meaningful differences favouring Selank on all four of the secondary endpoints listed above.

Sedation: minimal or absent in the Selank arm; expected and dose-related in the medazepam arm.

Motor impairment: no measurable effect in the Selank arm; modest decrements in the medazepam arm on coordination and reaction-time testing.

Cognitive impairment: no measurable effect in the Selank arm; the expected mild but detectable decrement on digit-symbol substitution and related measures in the medazepam arm.

Abuse liability and rebound: no rebound anxiety in the Selank arm at the one-to-four-week follow-up windows; mild rebound in the medazepam arm consistent with benzodiazepine-class behaviour.

The composite picture is of two anxiolytics with comparable end-of-treatment anxiolytic effect but substantially different side-effect profiles. For research designs that need to probe anxiety in the context of preserved cognition or attention, the differential matters substantially.

The trial body has the same methodological limitations as the broader Russian peptide-clinical evidence record. Most trials are smaller than would be expected from a Western anxiety-drug development programme; blinding is variable; the cross-centre methodological independence is limited; Western meta-analysis is sparse.

The benzodiazepine comparator chosen (medazepam) is not the most-potent benzodiazepine in the class — comparisons against high-potency comparators like alprazolam or clonazepam would be more challenging. The published trial body does not consistently use those high-potency comparators.

Long-term comparative work — beyond the two-week treatment window — is sparse. Whether the side-effect differential persists across months of chronic use, and whether Selank's anxiolytic effect maintains across the same window, is not as well-characterised as the acute-treatment data.

Selank's comparative-trial body is one of the most credible pieces of evidence in the cognitive-peptide field that a non-GABA-A anxiolytic mechanism can produce clinically meaningful effects. The compound has not progressed to Western regulatory approval, but the trial body provides a stronger evidence floor for the underlying enkephalinase-inhibition strategy than would otherwise exist.

For research designs that need an anxiolytic tool but cannot tolerate the cognitive and motor side effects of the GABA-A class, Selank is the best-characterised peptide-class option. The decades of mature Western clinical-trial methodology have not been applied to it, but the available data is consistent enough to support continued research interest.